{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:06:26Z","timestamp":1789632386987,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41401-026-01886-7","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T06:16:26Z","timestamp":1784700986000},"page":"3083-3095","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting JOSD2 degrades \u03b2-catenin to suppress colorectal cancer metastasis by disrupting RAS\/ERK\/\u03b2-catenin axis"],"prefix":"10.1038","volume":"47","author":[{"given":"Yue","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-han","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-ting","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-wei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-yu","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu-run","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-tong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run-qiu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-ming","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-yu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-bo","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao-jun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"1886_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2025.102666","volume":"104","author":"JJ Zhou","year":"2025","unstructured":"Zhou JJ, Yang QZ, Zhao S, Sun LH, Li RQ, Wang J, et al. Evolving landscape of colorectal cancer: global and regional burden, risk factor dynamics, and future scenarios (the Global Burden of Disease 1990\u20132050). Ageing Res Rev. 2025;104:102666.","journal-title":"Ageing Res Rev"},{"key":"1886_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1886_CR3","first-page":"233","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73:233\u201354.","journal-title":"CA Cancer J Clin"},{"key":"1886_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41575-024-00934-z","volume":"21","author":"A Canellas-Socias","year":"2024","unstructured":"Canellas-Socias A, Sancho E, Batlle E. Mechanisms of metastatic colorectal cancer. Nat Rev Gastroenterol Hepatol. 2024;21:609\u201325.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1886_CR5","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335\u201342.","journal-title":"N Engl J Med"},{"key":"1886_CR6","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","volume":"369","author":"JY Douillard","year":"2013","unstructured":"Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369:1023\u201334.","journal-title":"N Engl J Med"},{"key":"1886_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116685","volume":"175","author":"LB Sun","year":"2024","unstructured":"Sun LB, Xing JP, Zhou XP, Song XY, Gao SH. Wnt\/\u03b2-catenin signalling, epithelial-mesenchymal transition and crosslink signalling in colorectal cancer cells. Biomed Pharmacother. 2024;175:116685.","journal-title":"Biomed Pharmacother"},{"key":"1886_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-54890-9","volume":"9","author":"WK Kim","year":"2019","unstructured":"Kim WK, Kwon Y, Jang M, Park M, Kim J, Cho S, et al. \u03b2-catenin activation down-regulates cell-cell junction-related genes and induces epithelial-to-mesenchymal transition in colorectal cancers. Sci Rep. 2019;9:18440.","journal-title":"Sci Rep"},{"key":"1886_CR9","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.3892\/or.2017.5454","volume":"37","author":"XW Yuan","year":"2017","unstructured":"Yuan XW, Sun XT, Shi XL, Wang H, Wu GY, Jiang CP, et al. USP39 promotes colorectal cancer growth and metastasis through the Wnt\/\u03b2-catenin pathway. Oncol Rep. 2017;37:2398\u2013404.","journal-title":"Oncol Rep"},{"key":"1886_CR10","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.3892\/ol.2016.4331","volume":"11","author":"M Xu","year":"2016","unstructured":"Xu M, Wang SS, Song YU, Yao JH, Huang K, Zhu XJ. Apigenin suppresses colorectal cancer cell proliferation, migration and invasion via inhibition of the Wnt\/\u03b2-catenin signaling pathway. Oncol Lett. 2016;11:3075\u201380.","journal-title":"Oncol Lett"},{"key":"1886_CR11","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.7150\/ijbs.98907","volume":"20","author":"ZD Xuan","year":"2024","unstructured":"Xuan ZD, Chen C, Sun HM, Yang KN, Li JX, Fu ML, et al. NDR1\/FBXO11 promotes phosphorylation-mediated ubiquitination of \u03b2-catenin to suppress metastasis in prostate cancer. Int J Biol Sci. 2024;20:4957\u201377.","journal-title":"Int J Biol Sci"},{"key":"1886_CR12","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.3389\/fphar.2020.01311","volume":"11","author":"CM Zeng","year":"2020","unstructured":"Zeng CM, Zhao CX, Ge FJ, Li YK, Cao J, Ying MD, et al. Machado-Joseph deubiquitinases: from cellular functions to potential therapy targets. Front Pharmacol. 2020;11:1311.","journal-title":"Front Pharmacol"},{"key":"1886_CR13","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/s41418-020-00639-1","volume":"28","author":"L Krassikova","year":"2021","unstructured":"Krassikova L, Zhang B, Nagarajan D, Queiroz AL, Kacal M, Samakidis E, et al. The deubiquitinase JOSD2 is a positive regulator of glucose metabolism. Cell Death Differ. 2021;28:1091\u2013109.","journal-title":"Cell Death Differ"},{"key":"1886_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41392-023-01706-y","volume":"9","author":"T Yuan","year":"2024","unstructured":"Yuan T, Zeng CM, Liu JW, Zhao CX, Ge FJ, Li YK, et al. Josephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity. Signal Transduct Target Ther. 2024;9:11.","journal-title":"Signal Transduct Target Ther"},{"key":"1886_CR15","doi-asserted-by":"publisher","first-page":"4008","DOI":"10.1016\/j.apsb.2021.04.003","volume":"11","author":"MJ Qian","year":"2021","unstructured":"Qian MJ, Yan FJ, Wang WH, Du JM, Yuan T, Wu RL, et al. Deubiquitinase JOSD2 stabilizes YAP\/TAZ to promote cholangiocarcinoma progression. Acta Pharm Sin B. 2021;11:4008\u201319.","journal-title":"Acta Pharm Sin B"},{"key":"1886_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58923-y","volume":"16","author":"T Yuan","year":"2025","unstructured":"Yuan T, Liu Y, Wu RL, Qian MJ, Wang WH, Li YH, et al. Josephin Domain Containing 2 (JOSD2) inhibition as pan-KRAS-mutation-targeting strategy for colorectal cancer. Nat Commun. 2025;16:3623.","journal-title":"Nat Commun"},{"key":"1886_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113511","volume":"42","author":"YG Guo","year":"2023","unstructured":"Guo YG, Tian JX, Guo YJ, Wang C, Chen CC, Cai SW, et al. Oncogenic KRAS effector USP13 promotes metastasis in non-small cell lung cancer through deubiquitinating \u03b2-catenin. Cell Rep. 2023;42:113511.","journal-title":"Cell Rep"},{"key":"1886_CR18","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1038\/onc.2014.416","volume":"34","author":"E Lemieux","year":"2015","unstructured":"Lemieux E, Cagnol S, Beaudry K, Carrier J, Rivard N. Oncogenic KRAS signalling promotes the Wnt\/\u03b2-catenin pathway through LRP6 in colorectal cancer. Oncogene. 2015;34:4914\u201327.","journal-title":"Oncogene"},{"key":"1886_CR19","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1158\/0008-5472.CAN-11-3222","volume":"72","author":"D Horst","year":"2012","unstructured":"Horst D, Chen J, Morikawa T, Ogino S, Kirchner T, Shivdasani RA. Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signaling. Cancer Res. 2012;72:1547\u201356.","journal-title":"Cancer Res"},{"key":"1886_CR20","doi-asserted-by":"publisher","first-page":"e35826","DOI":"10.1371\/journal.pone.0035826","volume":"7","author":"P Krejci","year":"2012","unstructured":"Krejci P, Aklian A, Kaucka M, Sevcikova E, Prochazkova J, Masek JK, et al. Receptor tyrosine kinases activate canonical WNT\/\u03b2-catenin signaling via MAP kinase\/LRP6 pathway and direct \u03b2-catenin phosphorylation. PLoS One. 2012;7:e35826.","journal-title":"PLoS One"},{"key":"1886_CR21","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1053\/j.gastro.2005.02.067","volume":"128","author":"J Li","year":"2005","unstructured":"Li J, Mizukami Y, Zhang X, Jo WS, Chung DC. Oncogenic K-ras stimulates Wnt signaling in colon cancer through inhibition of GSK-3beta. Gastroenterology. 2005;128:1907\u201318.","journal-title":"Gastroenterology"},{"key":"1886_CR22","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"1886_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/iub.300","volume":"62","author":"JJ Sacco","year":"2010","unstructured":"Sacco JJ, Coulson JM, Clague MJ, Urb\u00e9 S. Emerging roles of deubiquitinases in cancer-associated pathways. IUBMB Life. 2010;62:140\u201357.","journal-title":"IUBMB Life"},{"key":"1886_CR24","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41568-023-00633-y","volume":"23","author":"G Dewson","year":"2023","unstructured":"Dewson G, Eichhorn PJA, Komander D. Deubiquitinases in cancer. Nat Rev Cancer. 2023;23:842\u201362.","journal-title":"Nat Rev Cancer"},{"key":"1886_CR25","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s12272-020-01281-8","volume":"43","author":"J Park","year":"2020","unstructured":"Park J, Cho J, Song EJ. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment. Arch Pharm Res. 2020;43:1144\u201361.","journal-title":"Arch Pharm Res"},{"key":"1886_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117324","volume":"287","author":"PW Liu","year":"2025","unstructured":"Liu PW, Chen ZY, Guo YT, He QJ, Pan CH. Recent advances in small molecule inhibitors of deubiquitinating enzymes. Eur J Med Chem. 2025;287:117324.","journal-title":"Eur J Med Chem"},{"key":"1886_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2025.108865","volume":"271","author":"C Torrado","year":"2025","unstructured":"Torrado C, Ashton NW, D\u2019Andrea AD, Yap TA. USP1 inhibition: a journey from target discovery to clinical translation. Pharmacol Ther. 2025;271:108865.","journal-title":"Pharmacol Ther"},{"key":"1886_CR28","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.2217\/fon.15.235","volume":"11","author":"X Liu","year":"2015","unstructured":"Liu X, Ji Q, Fan ZZ, Li Q. Cellular signaling pathways implicated in metastasis of colorectal cancer and the associated targeted agents. Future Oncol. 2015;11:2911\u201322.","journal-title":"Future Oncol"},{"key":"1886_CR29","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.cell.2012.05.012","volume":"149","author":"H Clevers","year":"2012","unstructured":"Clevers H, Nusse R. Wnt\/\u03b2-catenin signaling and disease. Cell. 2012;149:1192\u2013205.","journal-title":"Cell"},{"key":"1886_CR30","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1097\/CM9.0000000000002714","volume":"136","author":"YH Liu","year":"2023","unstructured":"Liu YH, Ma JJ, Lu SM, He PZ, Dong WG. USP25 promotes hepatocellular carcinoma progression by interacting with TRIM21 via the Wnt\/\u03b2-catenin signaling pathway. Chin Med J. 2023;136:2229\u201342.","journal-title":"Chin Med J"},{"key":"1886_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05593-7","volume":"14","author":"WW Wang","year":"2023","unstructured":"Wang WW, Lei YB, Zhang GY, Li XM, Yuan JH, Li TT, et al. USP39 stabilizes \u03b2-catenin by deubiquitination and suppressing E3 ligase TRIM26 pre-mRNA maturation to promote HCC progression. Cell Death Dis. 2023;14:63.","journal-title":"Cell Death Dis"},{"key":"1886_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05605-w","volume":"22","author":"YL Li","year":"2024","unstructured":"Li YL, Chen XY, Xiong YQ, Xu XQ, Xie CD, Min M, et al. BRCC36 regulates \u03b2-catenin ubiquitination to alleviate vascular calcification in chronic kidney disease. J Transl Med. 2024;22:820.","journal-title":"J Transl Med"},{"key":"1886_CR33","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1016\/j.molonc.2015.06.006","volume":"9","author":"SI Yun","year":"2015","unstructured":"Yun SI, Kim HH, Yoon JH, Park WS, Hahn MJ, Kim HC, et al. Ubiquitin specific protease 4 positively regulates the WNT\/\u03b2-catenin signaling in colorectal cancer. Mol Oncol. 2015;9:1834\u201351.","journal-title":"Mol Oncol"},{"key":"1886_CR34","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.7150\/ijbs.94013","volume":"20","author":"YH Liao","year":"2024","unstructured":"Liao YH, Liang JM, Wang YZ, Li A, Liu WB, Zhong BQ, et al. Target deubiquitinase OTUB1 as a therapeatic strategy for BLCA via \u03b2-catenin\/necroptosis signal pathway. Int J Biol Sci. 2024;20:3784\u2013801.","journal-title":"Int J Biol Sci"},{"key":"1886_CR35","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/cbin.12028","volume":"47","author":"HY Xie","year":"2023","unstructured":"Xie HY, Chen JY, Ma CY, Zhao JJ, Cui MH. UBP43 promotes epithelial ovarian carcinogenesis via activation of \u03b2-catenin signaling pathway. Cell Biol Int. 2023;47:1427\u201340.","journal-title":"Cell Biol Int"},{"key":"1886_CR36","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3892\/or.2015.4463","volume":"35","author":"W Ouyang","year":"2016","unstructured":"Ouyang W, Zhang SM, Yang B, Yang CX, Zhang JH, Zhou FX, et al. \u03b2-catenin is regulated by USP9x and mediates resistance to TRAIL-induced apoptosis in breast cancer. Oncol Rep. 2016;35:717\u201324.","journal-title":"Oncol Rep"},{"key":"1886_CR37","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00204-013-1035-3","volume":"87","author":"E Zeller","year":"2013","unstructured":"Zeller E, Hammer K, Kirschnick M, Braeuning A. Mechanisms of RAS\/\u03b2-catenin interactions. Arch Toxicol. 2013;87:611\u201332.","journal-title":"Arch Toxicol"},{"key":"1886_CR38","doi-asserted-by":"crossref","unstructured":"Han C, Fu YX. \u03b2-Catenin regulates tumor-derived PD-L1. J Exp Med. 2020;217:e20200684.","DOI":"10.1084\/jem.20200684"},{"key":"1886_CR39","doi-asserted-by":"publisher","first-page":"11221","DOI":"10.1074\/jbc.M611871200","volume":"282","author":"DX Fang","year":"2007","unstructured":"Fang DX, Hawke D, Zheng YH, Xia Y, Meisenhelder J, Nika H, et al. Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem. 2007;282:11221\u20139.","journal-title":"J Biol Chem"},{"key":"1886_CR40","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1002\/jcp.22527","volume":"226","author":"DP Ponce","year":"2011","unstructured":"Ponce DP, Maturana JL, Cabello P, Yefi R, Niechi I, Silva E, et al. Phosphorylation of AKT\/PKB by CK2 is necessary for the AKT-dependent up-regulation of \u03b2-catenin transcriptional activity. J Cell Physiol. 2011;226:1953\u20139.","journal-title":"J Cell Physiol"},{"key":"1886_CR41","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13046-019-1049-7","volume":"38","author":"JM Pan","year":"2019","unstructured":"Pan JM, Fan ZY, Wang ZQ, Dai QQ, Xiang Z, Yuan F, et al. CD36 mediates palmitate acid-induced metastasis of gastric cancer via AKT\/GSK-3\u03b2\/\u03b2-catenin pathway. J Exp Clin Cancer Res. 2019;38:52.","journal-title":"J Exp Clin Cancer Res"},{"key":"1886_CR42","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.cellsig.2012.12.006","volume":"25","author":"C Halleskog","year":"2013","unstructured":"Halleskog C, Schulte G. Pertussis toxin-sensitive heterotrimeric G(\u03b1i\/o) proteins mediate WNT\/\u03b2-catenin and WNT\/ERK1\/2 signaling in mouse primary microglia stimulated with purified WNT-3A. Cell Signal. 2013;25:822\u20138.","journal-title":"Cell Signal"},{"key":"1886_CR43","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1242\/jcs.01601","volume":"118","author":"MS Yun","year":"2005","unstructured":"Yun MS, Kim SE, Jeon SH, Lee JS, Choi KY. Both ERK and Wnt\/beta-catenin pathways are involved in Wnt3a-induced proliferation. J Cell Sci. 2005;118:313\u201322.","journal-title":"J Cell Sci"},{"key":"1886_CR44","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jhep.2010.10.021","volume":"55","author":"C Torre","year":"2011","unstructured":"Torre C, Benhamouche S, Mitchell C, Godard C, Veber P, Letourneur F, et al. The transforming growth factor-\u03b1 and cyclin D1 genes are direct targets of \u03b2-catenin signaling in hepatocyte proliferation. J Hepatol. 2011;55:86\u201395.","journal-title":"J Hepatol"},{"key":"1886_CR45","doi-asserted-by":"publisher","first-page":"7253","DOI":"10.1158\/0008-5472.CAN-10-1108","volume":"70","author":"L Mologni","year":"2010","unstructured":"Mologni L, Dekhil H, Ceccon M, Purgante S, Lan C, Cleris L, et al. Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2. Cancer Res. 2010;70:7253\u201363.","journal-title":"Cancer Res"},{"key":"1886_CR46","doi-asserted-by":"publisher","first-page":"e51449","DOI":"10.1371\/journal.pone.0051449","volume":"7","author":"L Mologni","year":"2012","unstructured":"Mologni L, Brussolo S, Ceccon M, Gambacorti-Passerini C. Synergistic effects of combined Wnt\/KRAS inhibition in colorectal cancer cells. PLoS One. 2012;7:e51449.","journal-title":"PLoS One"},{"key":"1886_CR47","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/cbin.11812","volume":"46","author":"Y Huang","year":"2022","unstructured":"Huang Y, Zeng JX, Liu T, Xu QY, Song XL, Zeng JH. Deubiquitinating enzyme JOSD2 promotes hepatocellular carcinoma progression through interacting with and inhibiting CTNNB1 degradation. Cell Biol Int. 2022;46:1089\u201397.","journal-title":"Cell Biol Int"},{"key":"1886_CR48","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330\u20137.","DOI":"10.1038\/nature11252"},{"key":"1886_CR49","unstructured":"Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell. 2017;169:1327\u201341.e23."}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01886-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01886-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01886-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:52:44Z","timestamp":1789631564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01886-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1886"],"URL":"https:\/\/doi.org\/10.1038\/s41401-026-01886-7","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Prof Bo Yang is one member\u00a0of\u00a0the the editorial board\u00a0of Acta Pharmacologica Sinica\u00a0and but she has not been involved in the peer-review or decision-making process for this manuscript.\u00a0The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}